Last $18.37 USD
Change Today +0.66 / 3.73%
Volume 163.9K
EPZM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Open
$17.85
Previous Close
$17.71
Day High
$18.77
Day Low
$17.85
52 Week High
01/10/14 - $41.23
52 Week Low
12/17/14 - $16.51
Market Cap
627.6M
Average Volume 10 Days
472.5K
EPS TTM
$-0.68
Shares Outstanding
34.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors. The company has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

74 Employees
Last Reported Date: 02/28/14
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $564.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $487.5K
Advisor
Total Annual Compensation: $513.2K
Advisor
Total Annual Compensation: $463.5K
Compensation as of Fiscal Year 2013.

epizyme inc (EPZM) Key Developments

Epizyme, Inc. Elects Kenneth Bate to Board of Directors

Epizyme, Inc. announced that Kenneth Bate has been elected to the Company’s board of directors. Mr. Bate is currently an independent consultant in the biotechnology field. Mr. Bate serves on the board of directors of four other public biopharmaceutical companies, AVEO Pharmaceuticals, Inc., BioMarin Pharmaceuticals, Inc., Genocea Biosciences, Inc. and Cubist Pharmaceuticals, Inc., where he is the chairman of the board of directors.

Epizyme Reports on PRMT5 Inhibitor in Vitro and in Vivo Activity in Models of Mantle Cell Lymphoma

Epizyme reported the results from a preclinical study showing in vitro and in vivo activity of its PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL). PRMT5 is an arginine methyltransferase (RMT), a subset of histone methyltransferases (HMTs), that is over expressed in multiple human malignancies, including MCL. EPZ015666 demonstrated potent killing of cancer cells in vitro and efficacy in animal models of MCL, with correlation to methyl mark inhibition. EPZ01566 is orally bioavailable and demonstrated dose-dependent inhibition of intracellular symmetric arginine di-methylation of SmD3, a PRMT5 substrate that plays a critical role in RNA processing. In pre-clinical studies, Z138 and Maver MCL cell lines were shown to be sensitive to EPZ015666, and in xenografts of these cell lines, the compound showed dose-dependent tumor growth inhibition. The PRMT5 clinical development program is part of a collaboration and license agreement with GSK.

Epizyme, Inc. Announces Results from the Phase 1 Dose Escalation Study of Investigational EZH2 Inhibitor EPZ-6438

Epizyme, Inc. announced results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 (referred to as E7438 by Eisai) administered orally as a single agent in patients with advanced solid tumors and B-cell non-Hodgkin lymphomas. This open-label, multicenter, Phase 1 study investigated EPZ-6438 as a single agent in patients with advanced B-cell non-Hodgkin lymphomas (diffuse large B-cell lymphoma = 6, follicular lymphoma = 5, marginal zone lymphoma = 1) or advanced solid tumors (colorectal = 4, INI1-deficient malignant rhabdoid tumor = 1, INI1-deficient synovial sarcoma = 1, other solid tumors = 6). The study objectives included establishment of the maximum tolerated or recommended Phase 2 dose, safety, tolerability, pharmacokinetics and preliminary evaluation of anti-tumor activity. Patients on study were heavily pre-treated, with fourteen patients having received between two and four prior therapies and nine having received more than four prior therapies. Five dosing cohorts were studied: 100 mg (n=6), 200 mg (n=3), 400 mg (n=3), 800 mg (n=6) and 1600 mg (n=6). As of October 20, 2014, the following activity was observed in the 20 patients with advanced B-cell NHL or advanced solid tumors who were evaluable for efficacy; four of 10 evaluable NHL patients achieved a partial response (PR) or better, including one complete response (CR); among five evaluable DLBCL patients, three achieved a PR or better: one patient with a PR reported in August 2014 subsequently evolved to a CR upon continued treatment and remains on study at 41 weeks of treatment; one of the two patients who achieved a PR remains on study; among four evaluable patients with follicular lymphoma (FL), one achieved a partial response and remains on study; three achieved stable disease (SD) and of these, two remain on study; confirmatory sequencing in a central laboratory showed all 10 NHL patients evaluable for efficacy had wild-type EZH2, and responses were observed in both germinal center origin and non-germinal center origin disease; one patient with an INI1-deficient malignant rhabdoid tumor achieved a PR and remains on study; 10 patients with solid tumors were evaluable for efficacy, including two patients with INI1-deficient solid tumors; EPZ-6438 was well tolerated, and the majority of adverse events were Grade 1 or Grade 2; responses were seen across a range of doses to 800 mg BID.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $18.37 USD +0.66

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies
 

Industry Analysis

EPZM

Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.2x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.